- Home
- News
- us virgislands
- urine testing
Refine by
Urine Testing Articles & Analysis
22 news found
High demand seen for effective disease management platform for second most common cancer in Singaporean men NEW YORK and SINGAPORE, March 28, 2022 /PRNewswire/ -- miR Scientific, a New York-based healthcare company dedicated to transforming global cancer management, and Leonie Hill Capital, a Singapore-based organization focused on large-scale, sophisticated healthcare access and distribution, ...
The global fertility services market is estimated to reach $45 billion by 2027. This opens up a massive opportunity for startups to innovate in the space. One of the most innovative startups is INTIN, the creator of a male sperm analyzer called OVIEW-M, which uses the camera on a smartphone to analyze sperm counts. They are also the creators of an at-home ovulation tester that uses salvia instead ...
Last month the company announced that miR Sentinel™ Prostate Cancer Test is commercially available in the United States, Puerto Rico and select international markets. miR Sentinel™ is a novel, urine-based, molecular test that analyzes small non-coding RNA using a proprietary biostatistical algorithm. ...
miR Sentinel™ is a novel, urine-based, molecular test that analyzes small non-coding RNA using a proprietary biostatistical algorithm. The miR Sentinel™ Test assesses the risk of aggressive prostate cancer and is intended to aid in the clinical management of men >45 years of age at risk for prostate cancer. ...
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Data presented from a cross-validation study at the American Urological Association's (AUA) 2021 Annual Meeting confirms that the miR Sentinel® Prostate Cancer Test can detect and risk-classify prostate cancer at the molecular level with predictive accuracy of over 90%, based on a single urine sample. ...
"The breakthrough miR Sentinel® Prostate Test developed by miR Scientific is non-invasive and can accurately detect prostate cancer as well as classify the risk category of the disease based only on a single urine specimen and without the need for invasive biopsies. ...
Urinalysis is a term used to describe a series of physical and chemical examinations performed on urine samples. This type of test is typically used for screening and diagnosis of Urinary Tract Infections (UTIs), renal or liver diseases, and diseases that originate in other parts of the body but can be detected through unusually high levels of certain ...
ByFluxergy
The second place went to the Turin-based start-up NIB Biotech, that has developed the first rapid urine test for the screening of prostate cancer, capable of contemporary identifying the presence and aggressiveness of a possible case of cancer, helping doctors determine whether a prostate biopsy is necessary. "A rapid test for ...
To alleviate the burden of invasive and costly standard surveillance methods on patients, urine collection was performed at home and shipped to a central lab to perform the Bladder EpiCheck test. ...
” About Bladder EpiCheck® Bladder EpiCheck provides patients and clinicians with a simple, objective urine test to detect recurrence of bladder tumors. The test analyzes subtle disease-specific changes in DNA methylation markers, allowing for the detection of 92% of the high-risk (non Ta-LG) cancers. ...
Salman will discuss the planned commercial launch of miR Scientific's first product, the miR Sentinel™ Prostate Test. The award-winning, highly accurate liquid biopsy urine test was recently designated Breakthrough Designation status by the Food and Drug Administration, and is expected to be launched commercially later this year. ...
Exosome Diagnostics is the world leader in developing exosomal liquid biopsy-based diagnostic assays. The EPI test is a non-invasive, urine-based genomic test that helps inform the prostate biopsy decision. ...
These funds will allow OncoDiag to market its Urodiag diagnostic test in France. Having obtained its CE mark in October 2018, the test is intended for patients being treated for low-grade or intermediate-risk non-muscle invasive bladder cancer (NMIBC), or those with a high risk of recurrence. The non-invasive urine test enables ...
ByOncoDiag
Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has published preliminary data on its kidney transplant rejection test, ExoTRU (Exosome Transplant Rejection Urine), a non-invasive multigene urine-based exosomal mRNA assay. ...
Salman will introduce miR Scientific's proprietary, highly accurate, award winning sncRNA interrogation platform, highlight its recent FDA breakthrough designation and present miR's commercial launch plans for its non-invasive liquid biopsy urine test. Mr. Salman will also introduce the company's product pipeline and global growth initiatives, including a ...
Salman will introduce miR Scientific's proprietary, highly accurate, award winning sncRNA interrogation platform, highlight its recent FDA breakthrough designation and present miR's commercial launch plans for its non-invasive liquid biopsy urine test. Mr. Salman will also introduce clinical collaboration roadmaps, the company's product pipeline and global growth ...
-Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, recently announced the launch of its BE Safe @Home project to bring surveillance for recurrence of non-muscle invasive bladder cancer (NMIBC) to patients’ homes with its Bladder EpiCheck® urine test. This initiative was developed after consulting with ...
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, recently announced the launch of its BE Safe @Home project to bring surveillance for recurrence of non-muscle invasive bladder cancer (NMIBC) to patients’ homes with its Bladder EpiCheck® urine test. ...
Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in BMC Urology, entitled A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy (available here). ...
The ExoDx™ Prostate (EPI) test played an important role in the management of Cal's prostate cancer. ...